Literature DB >> 8583785

Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats.

D J Campbell1, A M Duncan, A Kladis, S B Harrap.   

Abstract

When spontaneously hypertensive rats (SHR) treated at a young age with an inhibitor of angiotensin-converting enzyme (ACE) are withdrawn from treatment, their blood pressure (BP) remains below that of untreated rats. We examined the effects of ACE inhibitor treatment and its withdrawal on angiotensin-(1-7) [Ang-(1-7)], angiotensin II (Ang II) and angiotensin I (Ang I) in plasma, kidney, adrenal, heart, aorta, brown adipose tissue, lung, and brain of male SHR and normotensive Donryu rats. Rats were administered either vehicle or perindopril (3 mg/kg/day) from 6 to 10 weeks, from 6 to 20 weeks, and from 6 to 10 weeks, followed by perindopril withdrawal from 10 to 20 weeks. Angiotensin peptides and plasma levels of renin, angiotensinogen, ACE, and aldosterone were measured at 10 and 20 weeks of age. Perindopril reduced BP of both SHR and Donryu rats, although only SHR showed a reduction of BP of 19 mm Hg after perindopril withdrawal, associated with a reduction of 5% in heart weight/body weight ratio. Perindopril reduced the angiotensin II/angiotensin I ratio in all tissues by > 50%, with strain- and tissue-specific differences in the effects of perindopril on the levels of individual angiotensin peptides. None of the changes in Ang II levels persisted after perindopril withdrawal. In contrast to those of Donryu rats, plasma angiotensinogen levels of perindopril-withdrawn SHR were 14% lower than those of vehicle-treated SHR (p = 0.0356). Although the lower BP of perindopril-withdrawn SHR was not associated with an alteration in Ang II levels, the suppressed plasma angiotensinogen levels may have contributed to the lower BP of these rats. Alternatively, another action of perindopril, such as a change in cardiovascular structure, may have been responsible for the reduced BP of perindopril-withdrawn SHR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583785     DOI: 10.1097/00005344-199509000-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.

Authors:  Tammy C Lee; Dana Greene-Schloesser; Valerie Payne; Debra I Diz; Fang-Chi Hsu; Mitra Kooshki; Rashida Mustafa; David R Riddle; Weiling Zhao; Michael D Chan; Mike E Robbins
Journal:  Radiat Res       Date:  2012-06-12       Impact factor: 2.841

2.  Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.

Authors:  Helge Müller-Fielitz; Antonie Markert; Christian Wittmershaus; Friedrich Pahlke; Olaf Jöhren; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-03       Impact factor: 3.000

3.  Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.

Authors:  Anja Miesel; Helge Müller-Fielitz; Olaf Jöhren; Florian M Vogt; Walter Raasch
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 4.  Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target.

Authors:  Reza Aghamohammadzadeh; Sarah Withers; Fiona Lynch; Adam Greenstein; R Malik; Anthony Heagerty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.

Authors:  Michelle J Porritt; Michelle Chen; Sarah S J Rewell; Rachael G Dean; Louise M Burrell; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-21       Impact factor: 6.200

6.  Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance.

Authors:  Anura P Jayasooriya; Michael L Mathai; Lesley L Walker; Denovan P Begg; Derek A Denton; David Cameron-Smith; Gary F Egan; Michael J McKinley; Paula D Rodger; Andrew J Sinclair; John D Wark; Harrison S Weisinger; Mark Jois; Richard S Weisinger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.